Machine learning identifies cancer-busting ‘hyperfoods’

Several plant-based foods readily available in supermarkets contain bioactive molecules that could not only prevent cancer but also treat it, accomplishing the latter with protective mechanisms similar to those activated by existing clinical therapies.  

So found researchers at Imperial College London who combined machine learning with crowdsourced computing power to identify foods with the strongest cancer-beating molecules.

Rising to the top were tea, grapes, carrots, coriander, oranges, dill, cabbage and wild celery.

Scientific Reports published the study July 3.

Kirill Veselkov, PhD, and colleagues used an algorithm to replicate the effects of nearly 2,000 anticancer drugs, including 199 specifically designated as such, on human biological processes.

After validating their model—it predicted anti-cancer therapeutics with classification accuracy of 84% to 90%—the team fed it a sprawling database of close to 7,962 bioactive molecules present in foods.

With this, the model predicted 110 cancer-beating molecules would behave similarly to drug therapies from various chemical classes.  

These 110 molecules formed the basis of a resulting “food map” showing the plant-based consumables that contain the strongest potential for use in cancer prevention and treatment.  

In their discussion, Veselkov et al. state their methodology is “restricted to cancer and will be applicable to other health conditions. Moreover, it will pave the way to the future of hyperfoods and gastronomic medicine, encouraging the introduction of personalized ‘food passports’ to provide nutritious, tailored and therapeutically functional foods for every individual in order to benefit the wider population.”

Of note, the project tapped the power of a crowdsourced app, DreamLab, which draws surplus processing power from users’ smartphones to support cancer research.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”